Fujifilm Biotechnologies has announced the opening of its newly expanded medicine and vaccine factory on Teesside, following a substantial £400 million investment. The Japanese multinational, known for its production of biologics, vaccines, and advanced pharmaceuticals, has enhanced its Billingham site, making it the largest single-use contract development and manufacturing organisation (CDMO) in the United Kingdom.
The expansion project at the Billingham facility introduces new bioreactors that bolster the plant’s capacity to 19,000 litres. Spread over 110,000 square feet, this state-of-the-art factory is set to be fully operational by the first half of 2026. Fujifilm’s investment in this site aims to increase its capabilities in the development and manufacturing of complex medicines, targeting severe conditions such as cancer, neurodegenerative diseases, and rare disorders.
Additionally, the newly inaugurated Bioprocess Innovation Centre marks a significant leap in Fujifilm’s biomanufacturing capabilities. Doubling the site’s existing laboratory space, this 102,200 square foot facility will serve as a global centre of excellence for biomanufacturing and development work, solidifying Fujifilm’s commitment to innovative advancements in the biotech sector.
The expansion is poised to strengthen Fujifilm’s global manufacturing network, enhancing its capacity and competency in delivering advanced medicinal solutions. Currently, the site employs 960 individuals, reinforcing its role as a key player in the UK’s biotechnology and pharmaceutical landscape.
Fujifilm’s growth in the UK underscores its strategic initiative to address global healthcare challenges through innovation and expanded production capacity, affirming its position as a leader in the contract development and manufacturing organisation sector.
